193 related articles for article (PubMed ID: 36804071)
1. Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis.
Brandt L; Ritter K; Schneider-Thoma J; Siafis S; Montag C; Ayrilmaz H; Bermpohl F; Hasan A; Heinz A; Leucht S; Gutwinski S; Stuke H
Lancet Psychiatry; 2023 Mar; 10(3):184-196. PubMed ID: 36804071
[TBL] [Abstract][Full Text] [Related]
2. Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis.
Brandt L; Schneider-Thoma J; Siafis S; Efthimiou O; Bermpohl F; Loncar L; Neumann K; Hasan A; Heinz A; Leucht S; Gutwinski S
Lancet Psychiatry; 2022 Mar; 9(3):232-242. PubMed ID: 35183280
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
Winter-van Rossum I; Weiser M; Galderisi S; Leucht S; Bitter I; Glenthøj B; Hasan A; Luykx J; Kupchik M; Psota G; Rocca P; Stefanis N; Teitelbaum A; Bar Haim M; Leucht C; Kemmler G; Schurr T; ; Davidson M; Kahn RS; Fleischhacker WW
Lancet Psychiatry; 2023 Mar; 10(3):197-208. PubMed ID: 36716759
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
McEvoy JP; Byerly M; Hamer RM; Dominik R; Swartz MS; Rosenheck RA; Ray N; Lamberti JS; Buckley PF; Wilkins TM; Stroup TS
JAMA; 2014 May; 311(19):1978-87. PubMed ID: 24846035
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.
Schoretsanitis G; Kane JM; Correll CU; Rubio JM
Schizophr Bull; 2022 Mar; 48(2):296-306. PubMed ID: 34355232
[TBL] [Abstract][Full Text] [Related]
7. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
Højlund M; Kemp AF; Haddad PM; Neill JC; Correll CU
Lancet Psychiatry; 2021 Jun; 8(6):471-486. PubMed ID: 34023019
[TBL] [Abstract][Full Text] [Related]
8. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
Stroup TS; Bareis NA; Rosenheck RA; Swartz MS; McEvoy JP
J Clin Psychiatry; 2018 Nov; 80(1):. PubMed ID: 30549494
[TBL] [Abstract][Full Text] [Related]
10. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis.
Siafis S; Brandt L; McCutcheon RA; Gutwinski S; Schneider-Thoma J; Bighelli I; Kane JM; Arango C; Kahn RS; Fleischhacker WW; McGorry P; Carpenter WT; Falkai P; Hasan A; Marder SR; Schooler N; Engel RR; Honer WG; Buchanan RW; Davidson M; Weiser M; Priller J; Davis JM; Howes OD; Correll CU; Leucht S
Lancet Psychiatry; 2024 Jan; 11(1):36-46. PubMed ID: 38043562
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
[TBL] [Abstract][Full Text] [Related]
13. Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study.
Emsley R; Nuamah I; Gopal S; Hough D; Fleischhacker WW
J Clin Psychiatry; 2018 Jun; 79(4):. PubMed ID: 29924507
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
[TBL] [Abstract][Full Text] [Related]
15. Paliperidone palmitate for schizophrenia.
Nussbaum AM; Stroup TS
Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
Girardi P; Del Casale A; Rapinesi C; Kotzalidis GD; Splendori F; Verzura C; Trovini G; Sorice S; Carrus D; Mancinelli I; Comparelli A; De Filippis S; Francomano A; Ballerini A; Marcellusi A; Mennini FS; Ducci G; Sani G; Pompili M; Brugnoli R
Hum Psychopharmacol; 2018 May; 33(3):e2658. PubMed ID: 29766576
[TBL] [Abstract][Full Text] [Related]
20. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis.
Ostuzzi G; Vita G; Bertolini F; Tedeschi F; De Luca B; Gastaldon C; Nosé M; Papola D; Purgato M; Del Giovane C; Correll CU; Barbui C
Lancet Psychiatry; 2022 Aug; 9(8):614-624. PubMed ID: 35753323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]